Skip to main content
TipRanks
Go Ultimate75% OFF

Inoviq Ltd (EGQ0) AI Stock Analysis

1 Followers
DE:EGQ0

Inoviq Ltd

(Frankfurt:EGQ0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low leverageVery low leverage reduces financial risk and preserves flexibility while INOVIQ funds research, development and commercialisation. The limited debt burden should reduce interest and refinancing pressure, although it does not by itself solve the company’s ongoing losses or cash requirements.
Negative Factors
Sharp revenue declineThe steep revenue contraction shows that INOVIQ’s current commercial base remains very small and volatile. Lower revenue reduces operating leverage, makes research investment harder to fund internally, and weakens confidence that the existing business can support a sustainable growth trajectory.

Inoviq Ltd (EGQ0) vs. iShares MSCI Germany ETF (EWG)

-75%-50%-25%0%25%50%75%100%DE:EGQ0-64.20%EWG+3.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 16.89M
Dividend Yield
―
Average Volume (3M)
1,000
Price to Earnings (P/E)
-2.1
Beta (1Y)
-0.31
Revenue Growth
-22.61%
EPS Growth
10.75%
Country
Germany
Employees
15
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Inoviq Ltd Business Overview & Revenue Model

Company Description

INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current port...

Inoviq Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:EGQ0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:GSSAU:GSS50NeutralAUD 16.35M-1.14-35.10%―-9.10%31.75%
AU:BDXAU:BDX42NeutralAUD 22.20M-2.98-881.94%―743.51%-1.52%
AU:IBXAU:IBX40UnderperformAUD 4.02M-0.49165.88%―-100.00%-3.67%
AU:RHYAU:RHY38UnderperformAUD 21.84M-3.39-205.17%―239.64%-37.21%

* Healthcare Sector Average

Performance Comparison

0%100%DE:EGQ0AU:BDXAU:RHYAU:GSSAU:IBXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:EGQ0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:EGQ0Inoviq Ltd0.06-0.11-63.58%
AU:BDXBCAL Diagnostics Limited0.06-0.03-33.33%
AU:RHYRhythm Biosciences Ltd.0.06-0.04-36.84%
AU:GSSGenetic Signatures Ltd.0.07-0.20-73.82%
AU:IBXImagion Biosystems Ltd.0.01-0.01-52.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.